Discover IKK-beta Inhibitors with the Transcreener ADP2 Assay
The Transcreener ADP² Kinase Assay directly measures the ADP produced by IKK-beta (also known as IKBKB, inhibitor of kappa light polypeptide gene enhancer in B-cells, IKK-β, or IKK2). By measuring the production of ADP researchers can effectively determine the activity of the IKK-beta enzyme. The assay provides a powerful tool to screen entire compound libraries for IKK-beta modulators to help find new therapeutics for autoimmune diseases and cancer.
The Role of IKK-beta As Therapeutic Target
IKK-beta is a serine kinase in the NF-κB pathway. IKK aids in the activation of NF-κB by phosphorylating a bound inhibitor IκBα, allowing NF-κB to enter the nucleus, in turn, activating various inflammatory responses. The signaling pathway is part of the innate immune response to bacterial and viral material, among other stimuli. Incorrect regulation can lead to a number of conditions including inflammatory autoimmune disorders and cancer.
Direct Detection of ADP to Measure IKK Enzymatic Activity
The workhorse. Used in many large screens. Best deck and signal stability.
Positive FI signal. Compatible with simple fluorescence plate readers. Faster read time than FP or TR-FRET.
For customers who prefer TR-FRET detection. Uses the same filter set as HTRF®.
Learn why direct ADP detection is the best HTS assay method for Kinases and ATPases